The pathophysiological basis of bronchial asthma is non-infectious inflammation in the airways leading to bronchospasm, which causes bronchial asthma attacks. The first choice of bronchial asthma treatment is to give long-term anti-inflammatory therapy, and the drugs chosen are mainly inhaled hormones, and the main inhaled hormones currently used are budesonide, beclomethasone and fluticasone. During acute attacks of bronchial asthma, certain antispasmodic and antiasthmatic drugs should be given. The specific antispasmodic and wheezing drugs are as follows: 1) adrenergic agonists: such as salbutamol, terbutaline; 2) theophylline drugs: such as ammonium theophylline, theophylline extended-release tablets; 3) anticholinergic drugs: such as ipratropium bromide. To these drugs, some leukotriene modulators, such as montelukast, anti-allergy drugs, such as ketotifen, etc., can be added. In acute attacks of bronchial asthma, short-acting bronchodilators are preferred for treatment, such as short-acting beta agonists, salbutamol aerosols, and intravenous glucocorticoids, such as methylprednisolone and hydrocortisone.